Floatz logo

Dordaviprone

Gastric Mantle Cell Lymphoma

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Gastric Mantle Cell Lymphoma cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Dordaviprone is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
48 / 100
View asset →
triple-negative breast carcinomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →